COWZ vs IBB
Pacer US Cash Cows 100 ETF vs iShares Biotechnology ETF
- • IBB has the lower expense ratio at 0.44% vs 0.49% for COWZ.
- • COWZ pays a higher dividend yield (1.91%).
Side-by-side metrics
| Metric | COWZ | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.49% | 0.44% |
Dividend yield Trailing 12-month yield. | 1.91% | 0.16% |
AUM Assets under management — bigger funds are typically more liquid. | $19.78B | $11.50B |
YTD return | 18.58% | 30.22% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.62 | 0.60 |
P/E ratio | 15.96 | 25.48 |
Last price | $71.07 | $217.75 |
Inception | — | — |
Issuer | Pacer | iShares |
COWZ top holdings
| ACN | Accenture PLC Class A | 2.76% |
| LMT | Lockheed Martin Corp | 2.42% |
| COP | ConocoPhillips | 2.29% |
| MPC | Marathon Petroleum Corp | 2.28% |
| MO | Altria Group Inc | 2.26% |
| GILD | Gilead Sciences Inc | 2.25% |
| CVX | Chevron Corp | 2.25% |
| IBM | International Business Machines Corp | 2.19% |
| VLO | Valero Energy Corp | 2.15% |
| PFE | Pfizer Inc | 2.14% |
IBB top holdings
| GILD | Gilead Sciences Inc | 8.94% |
| AMGN | Amgen Inc | 8.31% |
| VRTX | Vertex Pharmaceuticals Inc | 7.87% |
| REGN | Regeneron Pharmaceuticals Inc | 6.24% |
| MRNA | Moderna Inc | 5.49% |
| NTRA | Natera Inc | 3.78% |
| ARGX | argenx SE ADR | 3.36% |
| BIIB | Biogen Inc | 2.52% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.50% |
| ILMN | Illumina Inc | 2.41% |
About COWZ
COWZ (Pacer US Cash Cows 100 ETF) is 100 Russell 1000 stocks with highest free cash flow yield. Managed by Pacer, the fund carries $19.8B in assets under management, an expense ratio of 0.49%, a dividend yield of 1.91%. Its largest holding is Accenture PLC Class A (ACN), which represents 2.8% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 9.6%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $11.5B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.16%. Its largest holding is Gilead Sciences Inc (GILD), which represents 8.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.